Clovis Oncology Inc
Change company Symbol lookup
Select an option...
CLVS Clovis Oncology Inc
GRRB Grandsouth Bancorp
BXRX Baudax Bio Inc
ZM Zoom Video Communications Inc
CIOXY Cielo SA
T AT&T Inc
PBCT People's United Financial Inc
PHK PIMCO High Income Fund
BAC Bank of America Corp
BHF Brighthouse Financial Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Price
Delayed
$6.63
Day's Change
0.105 (1.61%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.70
Day's Low
6.42
Volume
(Light)

Today's volume of 1,476,990 shares is on pace to be much lighter than CLVS's 10-day average volume of 4,616,575 shares.

1,476,990

Company Profile

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
3.76x
Price/Book (MRQ)
--
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

June 2020
Current Month
26.1M
Previous Month
27.2M
Percent of Float
30.26%
Days to Cover
5.8642 Days

Share Information

CLVS is in a share class of common stock
Float
86.1M
Shares Outstanding
87.9M
Institutions Holding Shares
195
37.00%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in millions.

Company Officers

  • Ginger L. GrahamChmn.
  • Patrick J. MahaffyPres.
  • Gillian C. Ivers-Read
  • Daniel W. MuehlCFO
  • Paul E. GrossExec.VP

Address

Insider Trading

During the most recent quarter, 53K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.